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Despite the increasing importance of long noncoding 
RNA in physiology and disease, their role in endothelial 
biology remains poorly understood. Growing evidence 
has highlighted them to be essential regulators of human 
embryonic stem cell differentiation. SENCR, a vascular-
enriched long noncoding RNA, overlaps the Friend 
Leukemia Integration virus 1 (FLI1) gene, a regulator of 
endothelial development. Therefore, we wanted to test 
the hypothesis that SENCR may contribute to mesoder-
mal and endothelial commitment as well as in endo-
thelial function. We thus developed new differentiation 
protocols allowing generation of endothelial cells from 
human embryonic stem cells using both directed and 
hemogenic routes. The expression of SENCR was mark-
edly regulated during endothelial commitment using 
both protocols. SENCR did not control the pluripotency of 
pluripotent cells; however its overexpression significantly 
potentiated early mesodermal and endothelial com-
mitment. In human umbilical endothelial cell (HUVEC), 
SENCR induced proliferation, migration, and angiogen-
esis. SENCR expression was altered in vascular tissue and 
cells derived from patients with critical limb ischemia and 
premature coronary artery disease compared to controls. 
Here, we showed that SENCR contributes to the regula-
tion of endothelial differentiation from pluripotent cells 
and controls the angiogenic capacity of HUVEC. These 
data give novel insight into the regulatory processes 
involved in endothelial development and function.
Received 19 November 2015; accepted 14 December 2015; advance online 
publication 5 April 2016. doi:10.1038/mt.2016.41
INTRODUCTION
Proangiogenic therapy to promote regeneration of damaged tis-
sue is a challenge for medicine. Human embryonic stem cells 
(hESC) offer a broad perspective to regenerative medicine due 
to their ability of self-renewal and differentiation into the three 
germ layers including mesoderm.1 Mesodermal commitment 
is dependent on epithelial to mesenchymal transition (EMT) 
described by the loss of epithelial marker CD326 and the acquisi-
tion of the neural cell adhesion molecule CD56.2 The mesoder-
mal specification is an important step in vascular development 
in controlling the de novo emergence of primordial endothelial 
cells (EC).3 The potential for hESC to form endothelium has 
been studied using 2D monolayer-directed differentiation or 3D 
embryoid body (EB) differentiation culture.4 However, a specific 
developmental stimulus sufficient to support the specification of 
large numbers of functional EC from hESC (hESC-EC) is poorly 
understood. Accordingly, the comprehension of the molecular 
mechanisms governing hESC fate is a crucial step for their clini-
cal use in cell-based therapies.
Noncoding RNAs (ncRNAs) have emerged to be essential 
regulators of cell function and identity. NcRNAs are classified by 
size and include long ncRNAs (lncRNA, >200 nucleotides) and 
small ncRNAs (<200 nucleotides) such as microRNA (miRNA). 
MiRNA play an important role in maintaining pluripotent state 
and stimulating differentiation of hESC including EC commit-
ment.5 LncRNA participate in a variety of biological processes, 
such as chromosome imprinting, epigenetic regulation, and 
reprogramming of induced pluripotent stem cells.6 Recently, 
functional lncRNA have emerged as novel regulators of hESC 
pluripotency and differentiation.7 However, the role of lncRNA in 
mesodermal and EC commitment and function is poorly under-
stood. Recently, FENDRR and BRAVHEART have been described 
as mesodermal-specific lncRNA and shown to be important for 
heart development.8,9 TIE1-AS was the first lncRNA described as 
an essential modulator of EC development and altered in patients 
with vascular malformation.10 ALIEN and PUNISHER have been 
identified to be orchestrators of cardiovascular commitment and 
EC function, respectively.11 Overall, these reports highlight the 
importance of lncRNA in the control of cell lineage specification 
during embryonic development.
SENCR is a human vascular-enriched lncRNA located on 
the chromosome 11 and existing as 2 isoforms including a full 
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length (SENCR V1) and an alternative spliced variant (SENCR 
V2)12 (Supplementary Figure S1). SENCR has been described 
to stabilize the differentiated state of human vascular smooth 
muscle cells (VSMC) and is transcribed antisense from the first 
intron of the Friend Leukemia Integration virus 1 (FLI1) gene.12 
FLI1 is a member of E26 Transformation-specific (ETS) fam-
ily expressed in the first step of EC development and is one of 
the earliest expressed transcription factors (TF) involved in EC 
specification.13
Since SENCR was found to be most abundant in EC and to 
correlate with expression of FLI1,12 we hypothesized that it may 
play a role during EC differentiation and in EC function. To inves-
tigate this, we developed two novel protocols allowing efficient EC 
differentiation from hESC using direct and haemogenic routes. 
We then profiled the dynamic regulation of SENCR during endo-
thelial differentiation. We further characterized its role in con-
trolling the mesodermal and endothelial commitment of hESC. 
Finally, we revealed an alteration of SENCR in vascular tissue and 
EC derived from patients with critical limb ischemia and prema-
ture coronary artery disease.
RESULTS
Differentiation protocols using direct routing or 
hemogenic endothelium formation allow generation 
of EC from hESC
To investigate the role of lncRNA during EC development, we 
established two novel protocols for the derivation of hESC-EC; 
direct and indirect, the latter routed through hemogenic endo-
thelium. For direct hESC-EC differentiation, H9 d0 hESC were 
forced into EB, plated out on d3 and cultured for 4 days in EGM-2 
(Figure 1a,b). At d7, EC markers CD144 and CD31 were increased, 
while pluripotency-marker TRA1-60 was decreased (Figure 1c, 
Supplementary Figure S2a top). Pluripotency-associated genes 
OCT4, NANOG, and SOX2 were decreased from d3 (Figure 1d), 
mesodermal genes BRACHYURY and MIXL1 peaked at d3 
(Figure 1e), and EC genes CD31 and CD144 were upregulated 
from d3 (Figure 1f). Similar results were obtained using H1 
hESC line (Supplementary Figure S2a bottom, Supplementary 
Figure S2b). D7 hESC-EC CD144+ and CD144- were purified and 
expanded for 7 days, then expression of EC markers CD144 and 
CD31 was analyzed (Supplementary Figure S3). After 7 days of 
expansion, CD144+ hESC-EC, coexpressing CD31, were able to 
form tube-like structures on matrigel (Figure 1g) supporting their 
functionality. Hemogenic endothelial cells (HEC) are progenitors, 
hypothesised to give rise to EC and hematopoietic progenitor cells 
(HP) during development,14 previously identified as CD144+CD
73−CD235a−CD43−CD117intermediate.15 EC generation through HEC 
was developed using the first 7 days of an HP differentiation pro-
tocol (Supplementary Methods, Figure 2a). By d7, we observed 
the formation of suspension HP (HPs), which bud off adherent 
HP (HPa). Within HPa cells, we identified a CD31+CD144+CD
235A−CD117−CD43mixedCD73mixed population with cells express-
ing either CD43 or CD73 (Supplementary Figure S4), similar 
to previously described for HEC.15 EC capacity of d7-9 HPa was 
examined by culturing d7, 8 or d9 HPa cells in EGM-2 medium 
containing FBS for 3, 2 or 1 day until d10 (hESC-EC d7+3, d8+2, 
d9+1 respectively). Generation of hESC-EC was efficient using 
3 days in EC culture media (hESC-EC d7+3) (Supplementary 
Figure S5). HESC-EC d7+3 formed confluent monolayers, with a 
reduction in budding and suspension cells (Figure 2b). HEC were 
cultured in HP and EC conditions to compare their EC and hema-
topoietic capacities (Figure 2a). The percentage of CD144+CD31+ 
cells was significantly higher in the hESC-EC d7+3 compared to 
d7 HEC and d10 HPs/a, and a decrease in TRA1-60+ cells was 
observed throughout differentiation (Figure 2c). Moreover, plu-
ripotent genes NANOG and OCT4 were downregulated from d3, 
and BRACHYURY expression peaked at d3 (Figure 2d,e). The 
EC-associated gene, CD144 was upregulated in d7 HEC, d10 HPa, 
in hESC-EC d7+3, and was observed only at very low levels in d10 
HPs (Figure 2f). CD31 was upregulated in all populations after 
d3, and its expression has been associated with both EC and HP 
cells (Figure 2f). CD43, a HP-associated gene, was more highly 
expressed in d10 HPs compared to d7 HEC and hESC-EC d7+3 
(Figure 2g).
CD326lowCD56high mesoderm progenitor populations 
during hESC-EC differentiation
Using direct and HEC routes, a population of mesodermal pro-
genitor (MP) appeared transiently at d3 and were identified as 
CD326lowCD56high as previously described2 (Supplementary 
Figure S6). CD326lowCD56high d3 population was isolated using 
fluorescence-activated cells sorting after direct EC differentia-
tion (Supplementary Figure S7a) and gene profile was analysed 
(Supplementary Figure S7b). This data supports emergence of 
early MP identified as CD326lowCD56high. These data suggest that 
these two protocols were able to efficiently generate CD144+CD31+ 
hESC-EC with a consistent EC phenotype allowing us to interro-
gate the role of SENCR in EC development.
SENCR is dynamically regulated in endothelial and 
erythroid derivatives of hESC
Because SENCR is enriched in EC and correlates with expression of 
FLI1,12 a regulator of EC development,13 we first quantified SENCR 
expression during EC differentiation using our protocol. We also 
profiled MALAT1 expression which is known to regulate EC func-
tion.16 During direct hESC-EC differentiation (Figure 3a), SENCR 
V1 but not V2 was upregulated at d3 and sustained in hESC-EC 
at d5 and 7. SENCR V2 and MALAT1 were upregulated at d5 and 
increased at d7. SENCR V1 was consistently induced to a higher 
level than SENCR V2 and MALAT1. During generation of EC 
through HEC (Figure 3b), SENCR V1 and V2 were induced from 
d3 and upregulated in d7 HEC, d7+3 hESC-EC, and d10 HPa/s. 
SENCR V1 was still the more highly induced variant. MALAT1 
was not modulated. During erythroid differentiation (Figure 3c), 
SENCR V1 was the higher expressed lncRNA in d10 haemangio-
blast. In d17 HP, SENCR V1 and V2 were silenced while MALAT1 
remained constantly upregulated. In d24 erythroid cells, SENCR 
V1 and V2 were switched off when MALAT1 was stably expressed. 
We concluded that SENCR V1 was consistently and highly upreg-
ulated in early endothelial progenitor and remained expressed in 
hESC-EC. As SENCR V1 (hereafter called SENCR) was the more 
abundant variant in hESC-EC, we focused on its role in differen-
tiation. Since FLI1 is the antisense gene of SENCR, we analysed 
any correlation between FLI1 and SENCR during differentiation. 
Molecular Therapy vol. 24 no. 5 may 2016 979
Official journal of the American Society of Gene & Cell Therapy
SENCR in EC Development and Function
Consistent with previous findings in mature vascular cells,12 
expression of SENCR and FLI1 was positively correlated during 
EC and HP differentiation (Supplementary Figure  S8). Time 
course expression demonstrated that FLI1 and SENCR were acti-
vated at d1 and were then constantly upregulated during EC dif-
ferentiation and in human umbilical endothelial cell (HUVEC)
(Supplementary Figure S9a). Expression of ETV2, an ETS factor 
upstream of FLI1,17 peaked at d5 then was silenced in d7 hESC-
EC and in HUVEC (Supplementary Figure S9a). However, 
ETV2 was more highly expressed compared to SENCR and FLI1 
in H9 hESC and in d1-2 EB (Supplementary Figure S9b). As 
cellular localisation is crucial to understand the potential func-
tion of lncRNA, we investigated expression of SENCR in intra-
cellular compartment. We found an equal distribution of SENCR 
between both nucleus and cytoplasm whereas NEAT exhibited a 
high selectivity for nuclear localisation in HUVEC and hESC-EC 
(Figure 3d). RNA FISH experiments confirmed the equal distri-
bution of SENCR in nucleus and cytoplasm in HUVEC compared 
to UBC and nuclear SNORD3 (Figure 3e)
SENCR overexpression does not impact on 
pluripotency
To assess whether SENCR may impact on hESC pluripotency, we 
used self-inactivating vesicular stomatitis virus-pseudotyped len-
tivirus (LV) vectors harbouring the SENCR sequence under the 
SFFV promoter (Figure 4a). SENCR overexpression by LV par-
ticles (Figure 4b,c) did not alter: the pluripotent and germ-layer 
gene expression profile of hESC (Figure 4d); the expression of 
pluripotency-associated surface markers TRA-1-60 and SSEA3 
(Figure 4e); and the colony shape of hESC (Figure 4f). These data 
revealed that SENCR overexpression was not sufficient to drive 
hESC to exit their pluripotent state.
SENCR overexpression potentiates the mesodermal 
and endothelial commitment of hESC
To understand whether the modulation of SENCR may regu-
late hESC-EC differentiation, we developed a transduction 
protocol allowing SENCR overexpression during EB develop-
ment (Figure 5a). Toxicity of LV infection was evaluated by flow 
Figure 1 Direct differentiation of human embryonic stem cells (hESC) to endothelial cell (EC). (a) Schematic representation of direct hESC-EC dif-
ferentiation. (b) Morphological analysis of H9 hESC, d3 EB, and d7 hESC-EC (scale bars 250 µm). (c) Fluorescence-activated cells sorting quantification for 
CD144/CD31 (left) and TRA1-60 (right) in H9 hESC, d3 EB, and d5-7 hESC-EC (n = 3, error bars = standard error of the mean). (d–f) Quantitative reverse 
transcription-PCR analysis of pluripotency (d), mesodermal (e), and endothelial (f) genes (n = 4, error bars = RQmax). (c–f) Repeated measures analysis of 
variance, Tukey’s post-hoc comparisons, *P < 0.05, **P < 0.01, ***P < 0.001 compared to d0. (g) Tubule formation analysis of d14 CD144+CD31+ hESC-
EC. d0 H9 hESC was used as a negative control and human umbilical endothelial cell as a positive control. Images taken at 10× magnification (scale bars 
represent 100 µm). n = 3; images are representative for sample group.
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cytometry (Supplementary Figure S10). SENCR was overex-
pressed 3 days postinfection and was also stably overexpressed 
7 days after transduction (Figure 5b). LV infection using vectors 
carrying the green fluorescence protein (GFP) under control of 
the SFFV promoter demonstrated an efficient GFP expression 
in EB 3 days postinfection (Figure 5c,d). SENCR overexpression 
reduced the expression of pluripotent (NANOG, OCT4), endoder-
mal (FOXA2), and ectodermal genes (NESTIN) but enhanced the 
expression of mesodermal genes (MESP1, MIXL1, BRACHYURY) 
(Figure 5e). Specific cardiac (NKX2.5), hematopoietic (RUNX1, 
SCL), and FLI genes were reduced while EC genes were unchanged 
(Figure 5f). Since exogenous SENCR enhanced mesodermal gene 
expression, we then investigated whether SENCR drives MP com-
mitment. An increase in CD326lowCD56high MP was observed 
3  days after SENCR overexpression while pluripotency-associ-
ated markers SSEA-3 and TRA1-60 were unchanged (Figure 6a) 
(Supplementary Figure S11a,b). EB overexpressing SENCR dis-
played a less compact and more irregular shape as well as a reduc-
tion in surface area (Figure 6b). EMT, characterized by a loss of 
epithelial gene such as CDH1, is a process governing the emergence 
of MP18 and we therefore wanted to understand the mechanism 
involved in this phenotype. A custom TaqMan Low Density Array 
identified stem cell adhesion molecules that were downregulated 
in EB overexpressing SENCR including CDH1 (Figure 6c). We 
found also that SENCR overexpression after 7 days, stimulated 
generation of hESC-EC expressing CD144+CD31+ (Figure 6d) 
(Supplementary Figure S11c) as well as increased expression of 
EC-genes (CD31, CD144, FLT1) and EC-miRNA (miR-27b, miR-
126) (Figure 6e,f). Collectively, these data revealed the potential 
role of SENCR in controlling the EC commitment from hESC 
through MP.
SENCR regulates proliferation, migration, and  
tube-like formation of HUVEC
Because SENCR expression remained elevated in hESC-EC, we 
investigated the role of SENCR in HUVEC. We first elucidated 
the response of SENCR expression in HUVEC subjected to treat-
ment with vascular endothelial growth factor (VEGF), a cytokine 
involved in biological activity of EC.19 VEGF stimulated HUVEC 
proliferation (Supplementary Figure S12a) and induced SENCR 
expression transiently and in a time dependant manner with a peak 
12 hours after stimulation (Supplementary Figure S12b) dem-
onstrating its role in physiology of EC. To understand the role of 
SENCR in EC, loss- and gain-of-function studies were performed in 
HUVEC transfected with siRNA-Pool or infected with LV, respec-
tively. SENCR knockdown and overexpression were confirmed by 
Figure 2 Indirect endothelial cell (EC) differentiation formation of embryonic stem cells (HEC). (a) Schematic representation of indirect hESC-EC 
differentiation. (b) Morphological analysis of d7 HEC and d7+3 hESC-EC (scale bars 250 µm). (c) Quantification of fluorescence-activated cells sorting 
for both CD144+CD31+ (left) and TRA1-60+ (right) in H1 hESC, d3 EB, d7 HEC, d7+3 hESC-EC, d10 HPs, and d10 HPa. (n = 3, error bars = SEM). (d–g) 
Quantitative analysis of pluripotent (d), mesodermal (e), endothelial (f), and hematopoietic (g) genes (n = 3, error bars = RQmax). (c–i) Repeated 
measures analysis of variance, Tukey’s post-hoc comparisons, *P < 0.05, **P < 0.01, ***P < 0.001 compared to d0 H1 hESC pluripotent control.
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RNA FISH and quantitative reverse transcription-PCR (Figure 7a). 
Moreover siRNA and LV did not impact on cellular localization of 
SENCR (Figure 7b). We examined the ability of SENCR to affect 
cell motility using the scratch “wound” healing assays in HUVEC. 
Silencing and overexpression of SENCR reduced and stimulated, 
respectively, the covering of wounded area after 12 hours suggesting 
that SENCR promotes EC migration (Figure 7c). Cell cycle was next 
analysed to understand whether SENCR modulation may cause cell 
cycle arrest. SENCR silencing led to an increase of cells in the G1 
phase supported by a decrease of cells in the S/G2 phase whereas 
its overexpression had the opposite effect (Figure 7d). Since migra-
tion and proliferation are important in angiogenesis, we focused on 
the impact of SENCR modulation in this process. Knockdown and 
overexpression of SENCR impaired and stimulated, respectively, 
capillary-like structures on matrigel (Figure 7e).
SENCR controls the expression of angiogenic-related 
genes in HUVEC
To understand the targeted gene modulated by silencing of 
SENCR, we next carried out a microarray analysis using siRNA-
treated cells. A schematic presentation (Figure 8a) shows that 
known migratory and angiogenic genes were downregulated after 
silencing of SENCR. We focused our study on CCL5, CEACAM1 
and CX3CL1 described as proangiogenic gene.20–23 We confirmed 
that knockdown of SENCR resulted in a decrease of these genes 
and its overexpression induced an upregulation of CCL5 and 
CX3CL1 (Figure 8b). As shown by Bell et al.,12 modulation of 
SENCR did not alter the expression of FLI1 in this scenario dem-
onstrating that SENCR regulated EC function independently of 
FLI1 (Figure  8b). These data revealed SENCR as a regulator of 
angiogenesis-related function in EC.
Figure 3 Regulation of SENCR in human embryonic stem cells (hESC) derivatives. (a–c) Histograms represent expression of SENCR V1, SENCR V2, and 
MALAT1 during: (a) Direct EC differentiation versus H9 hESC compared to d3 EB, d5-7 hESC-EC; (b) Indirect differentiation of hESC into  endothelial cells 
(EC) versus H1 hESC compared to d3 EB, d7 HEC, d7+3 hESC-EC, d10 HPa/s; (c) Erythroid differentiation versus H1 hESC compared to d10  haemangioblast 
(HG), d17 HP, d24 erythroid cells (ES). (a–c) Repeated measures analysis of variance, Tukey’s post-hoc comparisons, n = 3, *P < 0.05, **P < 0.01, ***P < 
0.005 compared to d0 (all error bars = RQmax). (d) Subcellular localization of SENCR and NEAT1 in human umbilical endothelial cell (HUVEC) (left) and d7 
hESC-EC (right) using RNA fractionation. The equal volumes of nuclear and cytoplasmic RNA, corresponding to equivalent numbers of cells were used for 
cDNA synthesis. The abundance of transcript in nuclear and cytoplasmic fraction was analysed by quantitative reverse transcription-PCR and normalized 
using UBC. (e) RNA FISH analysis targeting SENCR (red) versus UBC (green) and nuclear SNORD3 (green) in HUVEC (scale bars 25 µm).
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SENCR dysregulation is associated with premature 
coronary artery disease and critical limb ischemia
Since SENCR regulates angiogenic-related function in HUVEC, 
we interrogated whether SENCR alteration may be associated 
with angiogenesis dysfunction in human samples. SENCR level 
was reduced, versus control limb muscle sample, in human 
critical limb ischemia (CLI) (Figure 8c), an occlusive peripheral 
arterial disease resulting in inadequate perfusion of the limb.24 
Alterations in EC function are common to a variety of pathologies 
including CLI and coronary artery disease (CAD).25 Particularly, 
EC dysfunction has been associated with the premature onset 
of CAD.26 EC derived from the superficial forearm veins were 
Figure 4 SENCR overexpression does not impact on human embryonic stem cells (hESC) pluripotency. (a) Schematic representation of constructed 
recombinant lentivirus (LV) vectors harbouring SENCR sequence under SFFV promoter. LTR, long-terminal-repeat; Ψ = Psi, packaging signal; RRE, Rev response 
element; cPPT, central polypurine tract; SFFV, promoter of spleen focus-forming virus; wPRE, Woodchuck hepatitis virus posttranscriptional regulatory  element. 
(b) Experimental design used to transduce pluripotent H9 hESC. (c–f) All of measures were performed 3 days postinfection and LV-SENCR-infected group is com-
pared to LV-control infected group. (c,d) Gene analysis for SENCR expression (c) and pluripotent/germ-layer genes (d) by quantitative reverse  transcription-PCR 
(all error bars = RQmax). (e) Representative fluorescence-activated cells sorting and quantification of immunophenotype profile analysis for TRA-1-60 and SSEA-3 
(all error bars = SEM). (f) Image representing morphology of H9 hESC colony (scale bar 125 µm). (a–f) n = 3, Student’s t-test. ***P < 0.005.
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previously isolated from pre-CAD patients and healthy control 
subjects. These cells have a high expression of mature endothelial 
cell antigens vWF, CD31, CD146, and KDR, and lack expression 
of the haematopoietic antigen, CD45.27 This study demonstrated 
impaired proliferation, adhesion, and migration of vessel wall 
EC derived from the superficial forearm veins in these patients 
compared to matched control subjects.27 Consistent with these 
observations, we found that SENCR expression was significantly 
reduced in vessel wall EC isolated from patients with premature 
CAD compared to control subjects (Figure 8d). Collectively, these 
data showed that SENCR expression is down regulated in patients 
with EC dysfunction and atherosclerotic vascular disease.
DISCUSSION
We aimed to investigate the role of SENCR in EC differentiation 
and function by using two novel differentiation protocols allow-
ing efficient hESC-EC generation, through direct and haemo-
genic routes. We demonstrated that SENCR was regulated during 
hESC-EC commitment, and through gain-of-function study, we 
revealed SENCR as an early induced lncRNA capable of pro-
moting mesodermal and EC commitment. Therefore, loss- and 
gain-of-function experiments identified SENCR as a regulator of 
proliferation, migration, and angiogenesis in EC. Finally, altered 
SENCR expression was found in CLI tissues and in EC derived 
from premature CAD (Figure 8e).
SENCR is vascular-enriched lncRNA overlapping FLI1 gene,12 
a member of ETS family, which has been described as an early reg-
ulator of hemato-endothelial development.13,17,28 ETS factors are 
involved in developmental processes and ETS-binding sites are 
not specific for EC-expressed gene loci making difficult the com-
prehension of mechanisms involved in ETS factor-regulating EC 
specification. ETS factors controlling-EC gene depend on complex 
processes including binding partners, post-transcriptional modi-
fication and flanking sequence content.29 The functional role of 
ETS factors in EC fate has been, for example, explained by a prob-
able cooperative action with EC TF such as GATA-2.13 With tissue-
specific expression patterns during development, lncRNA may be 
orchestrators of this process and some reports have already related 
their role in specification of germ-layer9,11 and adult cells.9–11  
Here, we showed the dynamic regulation of a lncRNA, SENCR, 
and an overlapping ETS gene, FLI1, during hESC-EC differentia-
tion in precursor and differentiated hESC-EC. These data support 
a previous report associating induction of FLI1 to EC develop-
ment28 and revealed SENCR as an early mesodermal lncRNA 
Figure 5 SENCR overexpression during EB formation induces mesodermal genes expression. (a) Experimental design allowing SENCR 
 overexpression during EB formation. (b) SENCR expression analysis by quantitative reverse transcription-PCR 3 and 7 days post-transduction (all error 
bars = RQmax). (c–f) All of measures were performed 3 days postinfection. (c,d) Fluorescence microscopy (c, scale bar 125 µm) and quantification by 
 fluorescence-activated cells sorting of GFP+ cells (d) in EB infected with or without LV-GFP (all error bars = SEM). (e,f) quantitative reverse transcription-
PCR analysis showing the expression of pluripotent, mesodermal, endodermal, ectodermal (e), cardiac, endothelial, hematopoietic and FLI1 overlap-
ping gene (OV) (f) in LV-SENCR group compared to LV-control (all error bars = RQmax). (a–f) n = 5, Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.005.
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remaining expressed in hESC-EC. Addition of exogenous SENCR 
during EB formation increased the generation of MP expressing 
CD326lowCD56high and induced expression of mesodermal genes 
including BRACHYURY, MIXL1, and MESP1. EMT, controlling 
generation of MP, is mediated by TF such as MESP1 and character-
ized by the loss of epithelial genes such as CDH1.2 MESP1, through 
EMT, drives generation of cardiovascular MP including EC and 
VSMC whilst inhibiting the formation of other MP lineages such 
as HP.30 MESP1 was upregulated when CDH1 was downregulated 
after SENCR overexpression suggesting that SENCR can positively 
manipulate cardiovascular MP specification. This correlated with 
the fact that EB overexpressing SENCR failed to form compact 
structures and with a report which described CDH1 as a factor 
of EB aggregation.31 Exogenous SENCR also induced a downregu-
lation of extracellular matrix molecules such as COL2A1 and of 
β-integrins genes such as ITGB1, both pathways linked to cardiac 
specification.32 Moreover, a previous study related the size of EB to 
efficiency of EC differentiation33 suggesting that EB morphology 
Figure 6 SENCR overexpression potentiates the mesodermal and endothelial commitment of human embryonic stem cells. (a–c) All of measures 
were performed 3 days postinfection and LV-SENCR group is compared to LV-control group. (a) Histograms represent fluorescence-activated cells sorting 
analysis for MP CD326lowCD56high (left) and pluripotent marker TRA1-60+SSEA3+ (right). (b) Measure of area of EB by ImageJ expressed in µm2 (scale bar 
125µm) (all error bars = SEM). (c) Custom Taqman low-density array analysis of stem cells adhesion genes expression including cadherins (cadh), extracel-
lular matrix (ECM), α-integrins (α-int), β-integrins (β-int), focal adhesion (FA), and Src-Kinase (SRC) (n = 5, all error bars = RQmax). (d–f) All measures were 
performed 7 days postinfection and LV-SENCR group is compared to LV-control group. (d) Histogram representation of immunophenotype profiles of 
cells expressing endothelial cell markers CD144 and CD31 (n = 3, all error bars = SEM). (e,f) Endothelial genes (e) and miRNA (f) expressions analysed by 
quantitative reverse transcription-PCR (n = 3, all error bars = RQmax). (a–f) Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.005.
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Figure 7 SENCR controls proliferation, migration and tube like formation in human umbilical endothelial cell (HUVEC). (a) SENCR expression 
analysis by quantitative reverse transcription-PCR and RNA FISH (scale bar 25 µm) in HUVEC subjected to siRNA-Pool transfection targeted or not 
against SENCR (top) and to LV infection (bottom) (all error bars = RQmax). (b) Subcellular localization using RNA fractionation of SENCR in HUVEC 
subjected to siRNA transfection (top) and LV infection (bottom). (c) Following siRNA transfection (left) or LV infection (right) HUVEC were starved 
for 12 hours and mechanically disrupted with a sterile 200 µl tip, then photographed immediately at 0 and 12 hours latter. Migrated distance was 
measured as percentage by ImageJ and representative images are shown (scale bar 125 µm). (d) Percentage of cells in G0/G1 and S/G2 measured 
by flow cytometry following siRNA transfection (left) and LV infection (right). (e) Following siRNA transfection (left) or LV infection (right) HUVEC 
were starved for 12 hours and were allowed to sprout in a three-dimensional matrix for 12 hours. Cumulative sprout length was quantified using 
angiogenesis analyser for ImageJ and representative images are shown (scale bar 125 µm) (all error bars = SEM). (a–d) n = 3, Student’s t-test, 
*P < 0.05, **P < 0.01, ***P < 0.005.
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impacts on specification of vascular MP. Similarly, addition of 
exogenous SENCR resulted in a reduction in the size of EB. These 
demonstrated that SENCR may impact on the generation of vascu-
lar MP through molecular and morphological changes. NKX2.5, 
involved in cardiac development,34 as well as SCL and RUNX1, 
both involved in HP specification,35,36 were downregulated after 
SENCR overexpression while EC genes were unchanged reaffirm-
ing the hypothesis that SENCR is part of a molecular axis, driving 
vascular fate while inhibiting the formation of other mesodermal 
lineages.
Our observations revealed that exogenous SENCR impacts 
on vascular mesodermal specification, essential for EC develop-
ment,3,6 is in concordance with the findings that SENCR over-
expression led to an increase in CD31+CD144+ hESC-EC at 
d7 of differentiation. This was accompanied with an enhance-
ment in EC-specific genes and miRNA including CD144, CD31, 
FLT1, miR-126 and miR-27b. SENCR, and FLI1 shared the same 
expression profile throughout EC and erythroid differentiation 
highlighting their identical transcriptional regulation during 
development. To act at transcriptional level, ETS factors bind to a 
core “GGAA/T” binding element,37 and FLI1 itself is activated by 
ETV2 via an ETS binding site located -192 upstream its start site.17 
Therefore, analysis of genomic sequences revealed an ETS bind-
ing site -149 upstream SENCR start site, and transcription of both 
FLI1 and SENCR gene was activated from d1 of differentiation. 
Moreover, studies supported common TF activating both protein 
coding, and antisense lncRNA.38 Upon vascular development, 
ETV2 expression turns off and FLI controls its own expression 
through an auto-regulatory loop.17 Consistent with these state-
ments, expression of ETV2 was consistently increased on the first 
day of differentiation and silenced in fully differentiated hESC-
EC and in HUVEC. Moreover, FLI1 and SENCR expression was 
not dependant on ETV2 silencing at the end of differentiation. 
This asks the question of how SENCR remained expressed as well 
in EC. The influence of SENCR modulation on FLI1 expression 
and vice versa has not yet been described12 eliminating cis-acting 
effect on each other. Our gain- and loss-of-function experiment in 
HUVEC confirmed this fact; however, we found that expression of 
exogenous SENCR in EB led to a reduction of FLI1 transcription. 
This may be explained by the downregulation of SCL, induced by 
exogenous SENCR. Indeed SCL and FLI1 form a regulatory circuit 
controlling specification of HP by maintaining expression of each 
other.39 Nevertheless, despite the reduction of FLI1 in EB, its level 
seems to be sufficient to drive EC differentiation through MP in 
concert with exogenous SENCR transcript. Active transcription 
of SENCR during EC differentiation may be explained as FLI1 by 
a positive auto-regulatory loop similarly to the lncRNA HULC, 
in hepatocellular carcinoma which exists as part of an intricate 
auto-regulatory network resulting in an increase of its own expres-
sion.40 Another explanation of the high levels of SENCR expres-
sion in hESC-EC and cultured EC may be due to the stability of 
the RNA after post-transcriptional modification similar to ZFAS1 
lncRNA which is extremely stable and highly expressed in mouse 
neuroblastoma cells.41
SENCR was initially discovered as a vascular enriched 
lncRNA and described to inhibit migration and stimulate con-
tractile gene expression of VSMC.12 The function of SENCR in 
adult EC has not yet been studied; although its high expression in 
EC12 reflected its potential importance. Along this line, silencing 
and overexpression of SENCR impaired and enhanced, respec-
tively, sprouting of cultured EC as well as the expression of pro-
angiogenic genes including CCL5, CEACAM-1, and CX1CL3. 
Angiogenesis is a multistep process including a first step where 
EC migrate into the extracellular space, proliferate, and form 
capillary sprouts and tubular structures. CEACAM-1 is a trans-
membrane protein expressed on cell surface of capillary EC and 
has been described to stimulate angiogenesis through promigra-
tory process.23 In correlation with these observations, the migra-
tory capacity of EC was inhibited and stimulated after SENCR 
silencing and overexpression, respectively. Bell et al.12 described 
SENCR as a suppressor of promigratory phenotype in VSMC 
highlighting, its probable function in disease processes such as 
atherosclerosis where VSMC migration contributes to the patho-
genesis of neo-intima formation. Currently, treatments for CAD 
use drug-eluting stents allowing the delivery of a nonspecific 
antiproliferative agent acting on both VSMC and EC leading to a 
delay of re-endothelialisation and restenosis.42 Ideally, treatments 
would inhibit the VSMC proliferation and migration, whilst pro-
moting EC function. In this direction, SENCR is able to inhibit 
promigratory phenotype of VSMC while stimulating angiogen-
esis of EC similar to miR-126 which inhibits VSMC migration 
while restoring EC function in animal models of vascular balloon 
injury.43 The proangiogenic and promigratory effect induced by 
SENCR on cultured EC were also correlated in limb ischemia, 
pathology induced by vascular injury, where SENCR expression 
was altered. Consistent with that, CX3CL1, downregulated after 
SENCR silencing, has been demonstrated to significantly reverse 
limb ischaemia in a rat model via the induction of effective revas-
cularization.21 Amongst other genes, CX3CL1 simulates tissue 
neovascularization through the enhancement of EC prolifera-
tive capacity. Our findings showed that SENCR also impacts on 
cell cycle progression by stimulating cells to enter S/G2 phase. 
SENCR was also impaired in vessel wall EC, derived from patient 
with premature CAD, displaying defects in proliferative and 
migratory processes. The purpose of this study was to define a 
novel molecular mechanism that may have an application in the 
Figure 8 SENCR controls the expression of angiogenic-related gene and is altered in human sample derived from ischemic condition. (a) These 
figures illustrate genes with expressional changes after SENCR silencing belong to the cell migration (left) and angiogenesis (right). Gene expression 
profiles were uploaded to the Ingenuity Analysis Software and based on the differential expression of these genes, the most relevant biochemical 
network with functional links was assessed. (b) Quantitative reverse transcription-PCR was used to analyse expression of CX1CL3, CCL5, CEACAM1 as 
well as FLI1 in human umbilical endothelial cell subjected to siRNA transfection (top) and LV infection (bottom) (all error bars = RQmax), n = 3, Student’s 
t-test, *P < 0.05, **P < 0.01, ***P < 0.005. (c) Comparison of SENCR expression for the critical limb ischemia group (CLI, n = 10, *P < 0.05) versus con-
trol group (No-CLI, n = 9). (d) Comparison of SENCR expression for superficial forearm vein endothelial cells derived from premature coronary artery 
disease (CAD) group (Pre-CAD, n = 8, *P < 0.05) versus control group (Cont patient, n = 8) (all error bars = RQmax). Student’s t-test. (e) Schematic 
representation of the role of SENCR in hESC-EC differentiation and endothelial cell function.
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development of effective hESC-EC therapies for ischemic disease. 
Only a few reports have described the role of lncRNA in vascular 
development and pathology.29 For example, MALAT1 has been 
described to be significantly upregulated during hypoxia and 
controlling sprouting and migratory capacity of EC;44 however 
loss-of-function studies in mice revealed that it is not essential 
for development.7 TIE1-AS is the only lncRNA described to be 
essential for EC development and altered in human vascular 
injury.10 Here, we described for the first time an ETS-related 
lncRNA involved in EC development and function as well as its 
association with human vascular pathology.
MATERIALS AND METHODS
Cell culture. The hESC lines H1 and H9 (WiCell Research Institute, 
Madison, WI, http://wicell.org) were cultured in a feeder-free culture 
system on recombinant human vitronectin and using StemPro hESC 
serum-free medium (Life Technologies, CA) supplemented with 20 ng/
ml basic fibroblast growth factor (Peprotech, NJ). Cells were passaged 
mechanically using StemPro EZPassage mechanical stem cell passaging 
tool (Life Technologies Europe, Bleiswijk, Netherlands). Protocols allow-
ing generation of EC via direct and haemogenic routes are described in the 
Supplementary Method.
Study population. Tissue samples and vessel-wall derived EC were 
obtained from patients with critical limb ischemia (patients with (n = 9) 
or without (n = 10) critical limb ischemia from leftover limb muscle) and 
premature coronary artery disease (EC derived from the superficial fore-
arm veins, n = 8) respectively, following written informed consent, and 
in accordance with the Declaration of Helsinki. Patient characteristics 
and protocols for muscle biopsy and isolation of EC are described in the 
Supplementary Method (Supplementary Tables S5 and S6).
Reagents and other detailed methods are described in the 
Supplementary Method, Supplementary Tables S1 to S4 and 
Supplementary References.
SUPPLEMENTARY MATERIAL
Figure S1. Schematic representation of genomic localization of both 
version of SENCR and FLI1.
Figure S2. hESC-EC direct differentiation using the H9 and H1 hESC line.
Figure S3. MACSorting of d7 hESC-EC from direct differentiation.
Figure S4. Identification of a HEC population existing on d7 of an 
established hematopoietic differentiation protocol.
Figure S5. Optimisation of an indirect hESC-EC differentiation protocol.
Figure S6. Identification of CD326lowCD56high MP population during 
direct and indirect hESC-EC differentiation.
Figure S7. Purification and characterisation of a CD326lowCD56high 
MP population in hESC-EC differentiation.
Figure S8. Expression of FLI1 during differentiation of hESC into EC 
and erythroid cells.
Figure S9. Time course expression of ETV2, FLI1 and SENCR during 
hESC-EC differentiation and in HUVEC.
Figure S10. Assessment of toxicity after LV infection using Zombie 
aqua staining.
Figure S11. SENCR enhances differentiation of CD326lowCD56high 
and CD144+CD31+ hESC-EC.
Figure S12. SENCR expression analysis after VEGF treatment in HUVEC.
Table S1. Information for specific antibodies used in FACS analysis 
and sorting.
Table S2. Information for isotype control antibodies used in FACS 
analysis and sorting.
Table S3. Information for probes used in TaqMan-based quantitative 
real-time PCR assays.
Table S4. Primer-pairs used for SYBR-Green-based quantitative real-
time PCR assays.
Table S5. Clinical characteristics of patients with or without critical 
limb ischaemia, from whom leftover limb muscle samples from cardio-
vascular surgery were analysed.
Table S6. Clinical characteristics of patients with or without prema-
ture coronary artery diseases.
Methods.
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